Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf
11.23.2007
Pharmaceutical innovation in Europe, a call to action by Arthur Higgins - EFPIA president
In a recent conference in Portugal the EFPIA president adressed innovation issues in Europe and called for action on four areas, such as better patient access to new discoveries whereby Health Technology Assessment should not be used as a means of restricting access to new medicines, fair reward for innovation - including incremental innovation, strong intellectual property protection and new thinking to balance healthcare costs - shift away from the cost of medicines to their value.
No comments:
Post a Comment